The GW Cancer Center is proud of its physician scientists and their commitment to medical research. These clinical studies are designed to add to the medical knowledge base and relate to the treatment, diagnosis, and prevention of diseases or conditions.
|Malignant Hematology Program||A Global, Prospective, Non-Interventional, Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Patients-the INSIGHT-MM study||
The objective of this study is to describe contemporary, real-world patterns of patient characteristics, clinical disease presentation, therapeutic regimen chosen, and clinical outcomes in patients with newly diagnosed multiple myeloma and patients with relapsed/refractory multiple myeloma.
|Urological Oncology Program||A Phase 3 Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)||
This randomized phase III trial compares nephrectomy (surgery to remove a kidney or part of a kidney) with or without nivolumab in treating patients with kidney cancer that is limited to a certain part of the body (localized). Monoclonal antibodies, such as nivolumab, may interfere with the ability of tumor cells to grow and spread. Giving nivolumab before nephrectomy may make the tumor smaller and reduce the amount of normal tissue that needs to be removed, and after nephrectomy to increase survival. It is not yet known whether nivolumab and nephrectomy is more effective than nephrectomy alone in treating patients with kidney cancer.
|Melanoma and Cutaneous Oncology Program||Study of Pembrolizumab With or Without Platinumb-based Combination Chemotherapy Versus Chemotherapy Alone in Urothelial Carcinoma (KEYNOTE-361)||
The purpose of this study is to determine the efficacy and safety of pembrolizumab (MK-3475) with or without chemotherapy versus chemotherapy alone in participants with advanced or metastatic urothelial carcinoma (bladder cancer).
|Breast Cancer Program||Comparing Group Approaches to Improve Insomnia Symptoms Among Breast Cancer Survivors||
We are inviting women diagnosed with stage I-III breast cancer who have completed active treatment (e.g. surgery, chemotherapy, radiation) to participate in this research study. Through this study we will examine if our mind and body programs improve some of the long term effects of breast cancer treatment such as insomnia. This is a pilot phase of the study. This means that we are interested in feasibility of the program and will ask for your feedback about things you like and do not like about the program.
|Urological Oncology Program||A Phase III, Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer||
Men with newly diagnosed metastatic hormone sensitive prostate cancer and a PSA =2 ng/mL with be randomized to either Androgen deprivation therapy (LHRHa) + TAK-700 (ARM 1) or Androgen deprivation therapy (LHRHa) + Bicalutamide (ARM 2, also the standard of care arm). Patients will be followed for 10 years.
|Breast Cancer Program||Combination immunotherapy with Herceptin and the HER2 vaccine E75 in low and intermediate HER2- expressing breast cancer patients to prevent recurrence||
This is a randomized trial for after all neo or adjuvant therapy is complete for women are Her2 1+ or HER2 2+
|Urological Oncology Program||Investigational drug study (ipilimunab) for prostate cancer||
A Phase 2, Double-Blind Study of Ipilimumab Administered at 3mg/kg vs 10mg/kg in Adult Sujbects with Metastatic Chemotherapy-Naïve Castration Resistant Prostate Cancer Who are Asymptomatic or Minimally Symptomatic. The primary objective of this study is to estimate the radiographic progression-free survival of patients with chemotherapy-naïve castrate resistant prostate cancer patients randomized to ipilimumab 3mg/kg vs 10mg/kg
|Malignant Hematology Program||New treatment approach for multiple myeloma||
CC4047-MM-007: A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidamide, Bortezomib and Low-Dose Dexamethasone versus Bortezomib and Low-Dose Dexamethasone in subjects with Relapsed or Refractory Multiple myeloma The purpose of this study is to see how well the combination of pamalidomide, bortezomib and dexamethasone works compared to the combination of bortezomib and dexamethasone.
|Malignant Hematology Program||X05383: Retrospective Study to Evaluate the Incidence and Severity of Peripheral Neuropathy in Relapsed/Refractory Mulitple Myeloma Patients Retreated with Bortezomib||
Determining the incidence and change in severity of peripheral neuropathy upon retreatment of multiple myeloma patients with bortezomib as compared to initial bortezomib treatment